Clinuvel Pharmaceuticals (CHIA:CUV) - Stock Price, News & Analysis

CUV Stock Overview

CUV fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 55.3% below our estimate of its fair value

Earnings are forecast to grow 12.91% per year

Earnings grew by 14.2% over the past year

Risk Analysis

No risks detected for CUV from our risk checks.

Clinuvel Pharmaceuticals Limited Competitors

CSL

ASX:CSL

AU$133.1b

Probiotec

ASX:PBP

AU$230.1m

NeuroScientific Biopharmaceuticals

ASX:NSB

AU$6.9m

Voyager Therapeutics

NasdaqGS:VYGR

US$486.2m

Price History & Performance

Summary of all time highs, changes and price drops for Clinuvel Pharmaceuticals
Historical stock prices
Current Share Price	AU$15.06
52 Week High	AU$21.43
52 Week Low	AU$12.98
Beta	0.74
1 Month Change	-4.86%
3 Month Change	-3.59%
1 Year Change	-24.04%
3 Year Change	-47.47%
5 Year Change	-43.05%
Change since IPO	877.92%

Recent updates

Shareholder Returns

	CUV	AU Biotechs	AU Market
7D	-1.2%	0.2%	0.5%
1Y	-24.0%	-7.5%	6.2%

Return vs Industry: CUV underperformed the Australian Biotechs industry which returned -7.4% over the past year.

Return vs Market: CUV underperformed the Australian Market which returned 6.3% over the past year.

Price Volatility

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Average Weekly Movement	7.4%
Biotechs Industry Average Movement	10.8%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CUV has not had significant price volatility in the past 3 months.

Volatility Over Time: CUV's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	n/a	Philippe Wolgen	www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Clinuvel Pharmaceuticals Limited Fundamentals Summary

How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap?
CUV fundamental statistics
Market cap	AU$751.48m
Earnings (TTM)	AU$30.15m
Revenue (TTM)	AU$81.76m

24.9x

P/E Ratio

9.2x

P/S Ratio

Is CUV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CUV income statement (TTM)
Revenue	AU$81.76m
Cost of Revenue	AU$6.70m
Gross Profit	AU$75.06m
Other Expenses	AU$44.90m
Earnings	AU$30.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.60
Gross Margin	91.80%
Net Profit Margin	36.88%
Debt/Equity Ratio	0%

How did CUV perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

8%

Payout Ratio

CUV Stock Overview

Rewards

Risk Analysis

Clinuvel Pharmaceuticals Limited Competitors

ASX:CSL

AU$133.1b

ASX:PBP

AU$230.1m

ASX:NSB

AU$6.9m

NasdaqGS:VYGR

US$486.2m

Price History & Performance

Recent News & Updates

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Recent updates

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

Shareholder Returns

Price Volatility

About the Company

Clinuvel Pharmaceuticals Limited Fundamentals Summary

24.9x

9.2x

Earnings & Revenue

Dividends

0.3%